Nateglinide

Drug Profile

Nateglinide

Alternative Names: A 4166; AY 4166; Fastic; Glinate; Nategurinide; SDZ DJN 608; Senaglinide; Starlix; Starsis; YM 026

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Ajinomoto
  • Developer Ajinomoto; Astellas Pharma; Glenmark Pharmaceuticals Ltd; Novartis
  • Class Antihyperglycaemics; Aromatic amino acids; Cyclohexanes; Small molecules
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 11 Jul 2016 Generic equivalent approved in USA for Type-2 diabetes mellitus
  • 13 Jun 2016 No development reported - Phase-III for Type-2 diabetes mellitus (Combination therapy, Second-line therapy or greater) in Japan (PO)
  • 31 May 2015 Astellas Pharma withdraws NDA for use of nateglinide plus DPP4 inhibitors for Type 2 diabetes mellitus in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top